Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis

Background:Chronic obstructive pulmonary disease (COPD) is a widespread, heterogeneous disease characterized by chronic inflammation of the airway and the gradual blockage of air flow due to bronchial obstruction. At present, a large number of traditional Chinese medicine injections (TCMIs) has been applied in the clinical treatment of COPD. However, there is insufficient evidence of evidence-based medicine of the interaction between them. Therefore, the purpose of this study is through the network meta-analysis to evaluate the efficacy and safety of the different TCMIs treatment of COPD, offering reference and evidence for clinical application.Methods:We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata 13.0 software. Pulmonary function included forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), and FEV₁/FVC will be the primary outcomes, FEV₁ as a percentage of the estimated value (FEV₁%pred), maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value (MVV%pred), 6 minutes walking distance, The St. George''s Respiratory Questionnaire score, and safety/adverse event will be evaluated as secondary outcomes. Mean differences or odds ratios will be used for statistical analysis. We will ensure the reliability of the results through node-split model and heterogeneity analysis. In addition, methodological quality will be evaluated based on the Cochrane Collaboration''s tool, and the quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation system.Results:This study will provide reliable evidence for the clinical selection of TCMI in the treatment of COPD.Conclusion:The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.     

Moxibustion for stable chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis

Background:There is no optimal treatment to alleviate the decline of lung function in the stable phase of chronic obstructive pulmonary disease (COPD). The effectiveness of moxibustion as an adjunctive treatment for COPD in the stable phase has been reported clinically, but the conclusions on efficacy and safety have not been unified. This study will systematically evaluate the efficacy and safety of moxibustion on the treatment of COPD in the stable phase, providing clinical-based evidenceMethods:We will systematically search 7 literature databases and 2 clinical trial registration platforms. The searching time will be conducted from the establishment of databases to March 31, 2021, regardless of language. We will include the randomized controlled trial (RCT) evaluation of moxibustion combined with basic therapy vs basic therapy alone for the treatment of stable COPD. We will assess the risk of bias for individual RCTs using the Cochrane Handbook 5.1.0 evaluation tool. The primary outcome is forced expiratory volume in 1 second/forced vital capacity. The secondary outcomes include forced expiratory volume in 1 second, forced vital capacity, six-minute walking distance, COPD assessment test score, maximum ventilation, response to treatment, and incidence of adverse events. We will collect the effective data of individual RCT through systematic analysis of the random effect model. Heterogeneity will be tested by Cochran Q test and I-squared statistics. Two subgroup analyses will be performed to explore the sources of heterogeneity based on clinical experience. Excluding RCTs with a high risk of bias, fixed-effect model will be used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias will be assessed by funnel plot and Egger test.Results:This study will provide systematic evidence on the efficacy and safety of moxibustion on the treatment of patients with stable COPD through strict quality assessment and reasonable data synthesis. We hope that the results will be submitted to a peer-reviewed journal for publication.Conclusion:This systematic review will provide the best current evidence for the adjuvant treatment of stable COPD with moxibustion.INPLASY registration number:INPLASY202140047.     

Efficacy and safety of Shufeng Jiedu capsule in the treatment of COVID-19: A protocol for systematic review and meta analysis

Background:Coronavirus disease 2019 (COVID-19) epidemic is spreading worldwide. Shufeng Jiedu capsule (SFJDC) is a commonly used drug in the treatment of COVID-19. However, there is insufficient evidence for clinical efficacy and safety.Methods:Two authors will independently search the Chinese National Knowledge Infrastructure (CNKI), VIP database, Wanfang database, the Cochrane Library, EMBASE, PubMed and Web of Science, in English and Chinese. All analysis will be performed based on the Cochrane Handbook for Systematic Reviews of Interventions. Review Manager 5.3 and Stata 16.0 software will be used to analyze the eligible data.Results:This protocol will conduct a systematic review and meta-analysis of literature listed above, and reliable outcomes about the clinical efficacy and safety of SFJDC in the treatment of COVID-19 will be obtained.Conclusions:These findings will provide guidance for clinicians and patients using SFJDC for COVID-19 treatment.PROSPERO Registration Number:CRD42020185764.     

Effectiveness and safety of acupuncture for chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis

Background:Chronic Obstructive Pulmonary Disease (COPD) is the most common respiratory disease in clinic. Traditional Chinese medicine (TCM) lung rehabilitation has gradually been valued in the field of prevention and treatment of COPD. Acupuncture, as an important part of TCM lung rehabilitation, is carried out in clinical extensively and application. It has the advantage of improving the symptoms and quality of life of COPD cases, but the evidence-based proof is limited.Methods:Eight databases will be systematically retrieved from their inceptions to December 2021. This study will include randomized controlled trials of acupuncture in the treatment of COPD with stable stage. The main outcome will include clinical effective rate, TCM symptom score, quality of life, dyspnea, exercise capacity, lung function, frequency of acute exacerbation, adverse events. Literature screening, quality evaluation and information extraction will be completed by two independent researchers. Revman 5.3 software will be used to perform meta-analysis. Assessment of multiple systematic reviews-2 tool will be used for evaluating the methodological quality of systematic review (SR), grading of recommendations assessment will for rating the quality of evidence, and consolidated standards of reporting trials and Standards for Reporting Interventions in Clinical Trials of Acupuncture tool will for assessing the reporting quality of randomized controlled trials.Results:The findings of this SR will be presented at relevant conferences and submitted for peer-review publication.Conclusions:The findings of this SR will provide up-to-date summary proof for evaluating the effectiveness and safety of acupuncture for COPD.     

雾化吸入布地奈德混悬液对慢性阻塞性肺疾病急性加重期患者的治疗作用及安全性评估

目的　探讨短期雾化吸入布地奈德混悬液对慢性阻塞性肺疾病急性加重期（AECOPD）患者的治疗效果及安全性评估。方法　87例AECOPD患者被随机分为吸入激素组（31例）、全身激素组（27例）和对照组（29例）。三组均给予吸氧、抗感染、氨茶碱及止咳化痰等常规治疗。吸入激素组加用布地奈德混悬液氧气雾化吸入。全身激素组在常规治疗的基础上加用泼尼松龙40mg，静脉给药。三组均于治疗前及治疗7d后测定肺功能、动脉血气及空腹血糖、电解质。结果　治疗前，三组间各指标比较无明显差异。治疗后，三组肺功能及动脉血气较治疗前均有明显改善（P〈0．01或P〈0．05）；吸入激素组与全身激素组比较，除血糖外（P=0．044），各指标差异无显著性（P均〉0．05）；吸入激素组与对照组比较，除pH值外，肺功能、血气指标差异均显著，血糖、电解质比较差异无显著性（P均〉0．05）。结论布地奈德混悬液雾化吸入治疗AECOPD安全有效。     

Home-based versus outpatient pulmonary rehabilitation program for patients with chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis

Background:Although home-based pulmonary rehabilitation programs have been shown in some studies to be an alternative and effective model, there is a lack of consensus in the medical literature due to different study designs and lack of standardization among procedures. Therefore, the purpose of this study was to compare the efficacy of a home-based versus outpatient pulmonary rehabilitation program for patients with chronic obstructive pulmonary disease (COPD).Methods:Five electronic databases including Embase, PubMed, Scopus, Science Direct, and Cochrane Library will be searched in May 2021 by 2 independent reviewers. The reference lists of the included studies will be also checked for additional studies that are not identified with the database search. There is no restriction on the dates of publication or language in the search. The randomized controlled trials focusing on comparing home-based and outpatient pulmonary rehabilitation for COPD patients will be included in our meta-analysis. The following outcomes should have been measured: functional exercise capacity, disease-specific health-related quality of life, and cost-effectiveness measures. Risk ratio with a 95% confidence interval or standardized mean difference with 95% CI is assessed for dichotomous outcomes or continuous outcomes, respectively.Results:It was hypothesized that these 2 methods would provide similar therapeutic benefits.Registration number:10.17605/OSF.IO/5CV48.     

Efficacy and safety of Maxing Shigan Decoction in the treatment of chronic obstructive pulmonary disease: A protocol for a systematic review and meta-analysis

Background:Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world but is projected to be the 3rd leading cause of death by 2030. Chronic obstructive pulmonary disease is an important public health challenge, which can be prevented and treated. COPD is an important public health challenge, both preventable and treatable. In China, Maxing Shigan Decoction (MSD) has been used as a traditional Chinese medicine compound for the treatment of respiratory diseases for thousands of years. In order to evaluate the efficacy and safety of MSD in the treatment of COPD, we need to conduct meta-analysis and systematic reviews.Methods:The data comes from 7 publicly published databases, including: PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), EMbase, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Database(CBM), VIP Database, and Wanfang database. We will include randomized controlled trials (RCTs) to evaluate the effectiveness and safety of MSD in the treatment of COPD. Result measurement indicators include: TCM syndrome scores, lung function indicators, serum inflammatory factors, blood gas indicators, adverse reactions. RevMan 5.0 will be used for meta-analysis.Results:This study will provide high-quality evidence for the effectiveness and safety of traditional Chinese medicine therapy for COPD.Conclusion:The results of this study will help us determine whether MSD can effectively treat COPD.Ethics and dissemination:All analyses in this study are based on previously published research, so this study does not require ethical approval or patient consent. We will disseminate our findings electronically or in print by publishing results in peer-reviewed journals.OSF registration number:DOI 10.17605/OSF.IO/H5UNB.     

Effectiveness and safety of acupoint application for chronic obstructive pulmonary disease: A protocol for updated systematic review and meta-analysis

Background:Acute exacerbation is a primary cause of repeated hospitalization and death in chronic obstructive pulmonary disease (COPD) patients. Therefore, how to control the symptoms of COPD at stable stage and reduce the number of acute exacerbation is a hot spot of medical research. Acupoint application (AA) is a significant part of external treatment of traditional Chinese medicine (TCM), Previous researches have reported that AA can be applied to the treatment of COPD. Nevertheless, its effectiveness is still inconclusive. This systematic review (SR) and meta-analysis is designed to appraise its effectiveness and safety for the treatment of patients with COPD.Methods:Eight databases will be systematically retrieved from their inceptions to February 2021. Inclusion criteria are randomized control trials of AA combined with routine western medicine interventions in the treatment of COPD at stable stage. The primary outcomes we focus on comprise clinical effective rate, TCM symptom score, quality of life, dyspnea, exercise capacity, lung function, frequency of acute exacerbation, adverse events. The research screening, data extraction, and risk of bias assessment will be conducted by 2 individuals independently, and divergence will be adjudicated by a third senior investigator. The Stata 13.1 software will be used for meta-analysis. The confidence of evidence will be classified adopting grading of recommendations assessment, development and evaluation (GRADE) algorithm and methodological quality of this SR will be assessed using assessment of multiple systematic reviews-2 (AMSTAR-2) tool.Results:This SR will provide evidence-based medical proof for the treatment of COPD at stable stage by AA combined with conventional western medicine interventions. The findings of this SR will be presented at relevant conferences and submitted for peer-review publication.Conclusions:The findings of this SR will provide up-todated summary proof for evaluating the effectiveness and safety of AA for COPD.Registration number:INPLASY 202140080.     

The effectiveness of Du moxibustion for chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis of randomized clinical trials

Background:As a common respiratory disease, Chronic Obstructive Pulmonary Disease (COPD) develops progressively. Du moxibustion can effectively treat COPD, and no adverse reactions have been reported. This research mainly evaluated the efficacy and safety of Du moxibustion in the treatment of COPD.Methods:Seven databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literatures Database (CBM), Wanfang Database (WF), Chinese Scientific Journal Database (VIP)) will be searched for all relevant eligible randomized controlled trials (RCTs) from the date of establishment to January 6, 2021. No matter whether they were blind or not, and regardless of the language and type of publication, these experiments could be included. Two authors (YRZ, ARG) will search the database respectively, extract relevant data, and use the Cochrane bias risk tool to evaluate the quality of the literature. RevMan V5.3 software will be used for data processing.Results:The results of this research are mainly used to evaluate the efficacy and safety of Du moxibustion in the treatment of COPD.Conclusions:This systematical review is expected to provide evidence-based and valuable suggestions for Du moxibustion in the treatment of COPD.Study registration number:INPLASY202110045.     

The acupuncture-related therapy for stable chronic obstructive pulmonary disease: A protocol for systematic review and network meta-analysis

Background:Chronic obstructive pulmonary disease (COPD) has become a huge economic burden. Increasing randomized clinical trials have favored the efficacy of a specified kind of acupuncture-related therapies (ATs) for treating stable COPD. Nonetheless, comparative efficacy of different ATs for stable COPD remains unknown. Thus, the purpose of this network meta-analysis protocol aims to determine the optimal modality of ATs for treating stable COPD.Methods:Six Chinese and English mainstream databases, including PubMed, Cochrane Library, Embase, China Biomedical Literature Database, Chinese National Knowledge Infrastructure, and Wanfang Database, will be systematically retrieved. The time range of the literature search is from the establishment date of each database to July, 2021. The primary outcome measures will be pulmonary function and incidence of acute exacerbations. The secondary outcome measures will consist of 6-minute walking distance, St George''s Respiratory Questionnaire, and COPD assessment test. The methodological quality of included studies will be evaluated by Cochrane risk-of-bias tool and the quality of evidence will evaluated through Grading of Recommendations Assessment, Development, and Evaluation instrument. Network meta-analysis will be completed using STATA software.Results:A synthesis of current evidence of ATs for stable COPD will be provided in this study.Conclusion:This study will contribute to synthesizing the evidence regarding the comparative efficacy of different modalities of ATs for stable COPD. Therefore, it will yield decision-making reference to further assist clinicians in determining the optimal modality of ATs in the treatment of stable COPD.Study Registration:This protocol was registered in the international prospective register of systematic reviews (PROSPERO) with the registration number CRD42020166649.     

雾化吸入布地奈德混悬液治疗AECOPD疗效分析

目的观察雾化吸入布地奈德混悬液在慢性阻塞性肺疾病急性加重期（AECOPD）的疗效。方法将46例患者分为雾化吸入激素组23例,全身应用激素组23例,两组患者均给予常规吸氧、抗炎、扩张支气管、止咳、袪痰治疗。观察治疗10d后患者的呼吸功能,血气分析指标及不良反应发生率。结果两组患者治疗前各指标比较无明显差异,治疗后肺功能及血气分析指标均有显著改善,但雾化吸入激素组不良反应发生率明显低于全身应用激素组,两者相比差异显著（P〈0.05）,有统计学意义。结论布地奈德混悬液治疗AECOPD疗效可靠,安全,副作用少,临床值得推广。     

Efficacy and safety of high-flow oxygen therapy application for chronic obstructive pulmonary disease with acute hypercapnic respiratory failure: A protocol for systematic review and meta-analysis

Background:Presently, there are no reviews or meta-analyses comparing the efficacy and safety of high-flow oxygen therapy (HFOT) and noninvasive ventilation (NIV) as first-line treatment in exacerbated chronic obstructive pulmonary disease (COPD) patients. The present protocol is conceived to evaluate whether HFOT is noninferior to NIV in treatment of patients with COPD and acute hypercapnic respiratory failure.Methods:We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and the recommendations of the Cochrane Collaboration to conduct this meta-analysis. Reviewers will search the PubMed, Cochrane Library, Web of Science, and EMBASE online databases using the key phrases “high-flow oxygen therapy,” “chronic obstructive pulmonary disease,” and “acute hypercapnic respiratory failure” for all English-language cohort studies published up to April, 2021. The cohort studies focusing on assess the efficacy and safety of HFOT and NIV in the treatment of patients with COPD and acute hypercapnic respiratory failure will be included in our meta-analysis. The primary outcome is treatment failure, whereas the secondary outcomes included arterial blood gas analysis, dyspnea score, comfort score, mortality, and total ICU and hospital lengths of stay.Results:The trial is conducted to test the hypothesis that HFOT, administered immediately after extubation, is not inferior to the NIV in reducing the rate of treatment failure in patients with COPD who were previously intubated due to hypercapniac respiratory failure.Registration number:10.17605/OSF.IO/Z2PEJ.     

Clinical therapeutic effects of high-flow nasal oxygen therapy in patients with acute exacerbation of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis

Background:For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated by respiratory acidosis, noninvasive ventilation therapy is thought to be the first-line treatment. In patients with AECOPD, the effect of high-flow nasal oxygen therapy is not well studied. In this study, the existing data will be synthesized to obtain an effective rate of movement of nasal oxygen therapy in patients with AECOPD.Methods:Using PubMed, EMBASE, Cochrane Library, Web of Science, Scopus, a systematic search will be undertaken to identify randomized controlled trails (RCTs) on the clinical therapeutic effects of rate of movement of nasal oxygen therapy in patients with AECOPD without language constraints from their onset to November 2020. To classify potentially qualifying tests, we will also review Google Scholar, ClinicalTrials.gov, and the reference lists of included studies. Two independent reviewers will review inclusion trials and execute data extraction. Research bias and quality will be measured using the Cochrane Collaboration Bias Method 2.0. The findings of the analysis will be pooled using a formula of fixed-effects or random-effects. We will address any dispute by dialogue, and cases of disagreement will be mediated by a third author.Results:The current research will examine the clinical therapeutic results of patients with AECOPD with rate of movement of nasal oxygen therapy.Conclusion:To assess the efficacy of rate of movement of nasal oxygen therapy in patients with AECOPD, the present analysis would provide consistent facts.OSF registration number:November 18, 2020.osf.io/umd48. (https://osf.io/umd48/).     

Efficacy of acupuncture combined with traditional Chinese medicine on chronic prostatitis: A protocol for systematic review and meta-analysis

Background:Chronic prostatitis is a common andrological disease, which brings many troubles to the lives of middle-aged and elderly male patients. With the increase of modern life pressure, the incidence of chronic prostatitis tends to younger, but its etiology and pathogenesis are not fully elucidated. Which seriously affects men''s health? Relevant studies have shown that acupuncture combined with traditional Chinese medicine (TCM) has a good effect on the treatment of chronic prostatitis compared with conventional western medicine; however, there is no consistent conclusion at present. The main purpose of this study is to explore whether acupuncture combined with TCM is effective in treating chronic prostatitis.Methods:The collection of randomized controlled trials related to acupuncture and TCM for chronic prostatitis will search the following electronic databases, including: PubMed, Web of Science, the Cochrane Database, EMBASE, Chinese National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, Weipu. There are 8 electronic databases including the VIP Chinese Science and Technology Periodical Database and the China Biomedical Literature Database. The cure rate and total effective rate are the main indicators, and the recurrence rate and adverse events are the secondary indicators. Meta-analysis using RevMan5.4 provided by Cochrane Collaboration.Results:This study will provide the latest evidence of efficacy for the acupuncture combined with TCM in the treatment of chronic prostatitis.Conclusion:The effectiveness of acupuncture combined with TCM for chronic prostatitis will be evaluated.Unique INPLASY number:INPLASY202130083.     

雾化吸入布地奈德治疗慢性阻塞性肺疾病急性加重期的研究

目的观察吸入布地奈德混悬液在慢性阻塞性肺疾病急性加重期（acute exacerbation of COPD,AECOPD）的疗效及安全性。方法将92例AECOPD的住院患者分为布地奈德组、强的松组和安慰剂组进行随机单盲对比观察。观察三组在用药后2h、72h、疗程结束（10d）时的呼吸困难评分、肺功能改善情况及不良反应。结果布地奈德组在开始治疗后2h呼吸困难分级改善明显,与其它两组比较差异有统计学意义;布地奈德组与强的松组在治疗后10d呼吸困难症状及肺功能均有显著改善,与安慰剂组比较差异有统计学意义。强的松组有2例出现血糖增高,1例出现上消化道出血。结论吸入布地奈德及口服强的松对AECOPD的短期疗效肯定,但吸入布地奈德起效快,副作用少,可以作为治疗AECOPD口服强的松的替代药。     

Effectiveness and safety of traditional Chinese medicines for pulmonary heart disease: A protocol for systematic review and meta-analysis

Background:Previous review indicate that the effect of traditional Chinese medicines (TCM) on pulmonary heart disease (PHD) remains uncertainty. Therefore, we designed this study to systematically evaluate the effectiveness and safety of TCM in the treatment of PHD.Methods:Nine online databases will be searched from inception to October 01, 2021, and we will not restrict the language on included trials. Randomized controlled trials that included patients with PHD receiving TCM therapy vs a control group will be included. Two of us will perform independently the selection of studies, risk of bias assessment, and data extraction. The RevMan V.5.2 software with fixed effects model or random effects model will be used to syntheses the data, according to the heterogeneity test to conduct the data synthesis. The dichotomous data and the continuous data will be presented with risk ratios with 95% confidence intervals and weighted mean differences or standardized mean differences with 95% confidence intervals. And we will use the Grading of Recommendations Assessment, Development, and Evaluation system to evaluate the evidence quality.Result:This study will assess effects and safety for TCM on PHD.Conclusion:The conclusion of this study will provide evidence to prove the safety and effectiveness of TCM on PHD.Trial registration number:INPLASY2020120024.     

Efficacy of acupuncture combined with Chinese herbal medicine for the treatment of chronic nephritis: A protocol for systematic review and meta-analysis

Background:Chronic nephritis is a common kidney disease that afflicts people worldwide. The disease has main manifestations of proteinuria, hematuria, edema, and hypertension that are associated with kidney-damaging processes that eventually lead to kidney failure. Traditional Chinese medicine involving combination treatment with herbal remedies and acupuncture has been shown clinically to alleviate chronic nephritis, although to date no systematic review of the efficacy of this combination treatment for this purpose has been reported, prompting this study. Here we conducted a systematic review and meta-analysis of published randomized clinical trials to scientific evidence and credible medical references supporting the clinical efficacy of this combination treatment when used to treat chronic nephritis.Methods:We will search the following 8 electronic Chinese and English databases: Web of Science, PubMed, Cochrane Library, Embase, China Biomedical Literature Database, China National Knowledge Infrastructure, China Scientific Journal Database, and the Wanfang database. All electronic databases will be searched from inception to October 10, 2021. All statistical analyses will be performed using Review Manager Version 5.4 provided by the Cochrane Collaboration Network.Results:The protocol for systematic review and meta-analysis will be applied to evaluate the efficacy of acupuncture combined with Chinese herbal medicine for the treatment of chronic nephritis.Conclusion:We plan to submit the results of this research to a peer-reviewed journal.INPLASY registration number:INPLASY2021100051.     

糖皮质激素延迟给药治疗AECOPD的疗效分析

目的探讨糖皮质激素（激素）延迟给药对慢性阻塞性肺疾病急性加重期（AECOPD）患者临床疗效的影响。方法治疗组：激素延迟72h给药治疗AECOPD患者共63例。对照组：明确诊断后即予激素治疗,共65例。观察FEV1、PaO2、PaCO2及呼吸困难评分的改善情况。结果治疗组与对照组比,FEV1、PaO2、PaCO2和呼吸困难评分改善更加明显,治疗前后相比差异有统计学意义（P〈0．05）。结论激素延迟72h给药治疗AECOPD患者疗效更加显著。     

莫西沙星治疗慢性阻塞性肺疾病急性加重最新临床试验(MAESTRAL研究)结果解读

慢性阻塞性肺疾病(COPD)急性加重(AECOPD)是COPD自然病程中的重要事件,不但可导致肺功能进行性下降,而且还是与病死率和病残率升高、生活质量下降相关的主要因素。此外,因AE-COPD住院治疗可明显增加医疗费用。目前AECO-     

AECOPD合并低钠血症临床研究

目的 探讨AECOPD合并低钠血症患者的临床特点和治疗方法.方法 观察组56例,随机抽取同期诊断为AECOPD且血钠正常的患者56例为对照组,对两组资料进行对比分析.结果 观察组与对照组相比,病程较长,吸烟指数大,出汗多,心律失常发生率高,呼吸频率增快,意识障碍患者数量多且病情重,COPD分级重度及极重度多,血钾及血氯降低,血气分析pH值、动脉血氧分压及动脉血氧饱和度降低,动脉血二氧化碳分压上升,住院天数延长,好转率下降,死亡率上升,均有统计学意义（P＜0.01,P＜0.05）.结论 临床上应予高度重视,提高对低钠血症的认识,做到早期发现、早期诊断、早期治疗,以提高治愈好转率,降低病死率.